Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712878 · ClinicalTrials.gov registry record · Phase 2
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03712878 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 10 participants.
The verdict
NCT03712878, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase II trial studies how well a 2-step approach to stem cell transplant works in treating patients with blood cancers. Giving chemotherapy and total body irradiation before a lymphocyte (white blood cell) and stem cell transplant helps stop the growth of cells in the bone marrow including normal blood-forming cells (stem cells) and cancer cells. By giving the donor cells in two steps, the dose of lymphocytes given can be tightly controlled and they can be made more tolerant to the body. When the healthy lymphocytes and stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells called graft versus host disease. Giving tacrolimus and mycophenolate mofetil may stop this from happening.
Interventions
- DRUG Cyclophosphamide
- RADIATION Total-Body Irradiation
- DRUG Tacrolimus
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
- PROCEDURE Donor Lymphocyte Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2025-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712878
The ClinicalTrials.gov registry entry for NCT03712878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03712878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712878 about?
NCT03712878 is a clinical study titled "2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies". This phase II trial studies how well a 2-step approach to stem cell transplant works in treating patients with blood cancers. Giving chemotherapy and total body irradiation before a lymphocyte (white blood cell) and stem cell transplant helps stop the growth of cells in the bone marrow including nor...
What is the current status of trial NCT03712878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-09-19. Estimated completion is 2025-03-19.
What interventions are being tested in trial NCT03712878?
The interventions under investigation include: Cyclophosphamide (DRUG), Total-Body Irradiation (RADIATION), Tacrolimus (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE), Donor Lymphocyte Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT03712878?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.